Asthma and lower airway diseaseNovel immunologic classification of aspergillosis in adult cystic fibrosis
Section snippets
Study design
This was a single center, 2-year prospective observational cohort study of adult patients with CF. The study was approved by the South Manchester research ethics committee (07/Q1403/70).
Patients and sample processing
Patients were enrolled from the Manchester adult CF center during outpatient consultations, and all gave written informed consent. Patients enrolled were aged 18 years or older and had a confirmed diagnosis of CF by genetic testing and/or sweat testing. Enrollment was deferred if they had an exacerbation of
Results
One hundred fifty patients consented to participate; 146 completed the study. Baseline clinical characteristics are shown in Table I.
Discussion
This study demonstrates the presence of 3 distinct classes of aspergillosis in adult patients with CF with respect to multiple biomarkers of Aspergillus infection and immunologic response to that infection or exposure: ABPA-S, sensitization, and Aspergillus infection/bronchitis.
This study moves the field forward in several ways and suggests that it is time to revise the 9-year-old consensus statement.3 First, we have provided a quantitative evidence base on which to make the diagnosis of
References (40)
- et al.
Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Chest
(1999) - et al.
Serologic IgE immune responses against Aspergillus fumigatus and Candida albicans in patients with cystic fibrosis
Chest
(2002) - et al.
The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in cystic fibrosis patients
Chest
(2010) - et al.
Aspergillus bronchitis in cystic fibrosis
Chest
(2006) - et al.
Homogenisation of cystic fibrosis sputum by sonication – an essential step for Aspergillus PCR
J Microbiol Methods
(2011) - et al.
Laboratory diagnosis of invasive aspergillosis
Lancet Infect Dis
(2005) - et al.
Accuracy of bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review
Chest
(2010) - et al.
Serologic diagnosis of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis through the detection of immunoglobulin G to Aspergillus fumigatus
Diagn Microbiol Infect Dis
(2008) - et al.
Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic fibrosis Foundation Consensus Conference
Clin Infect Dis
(2003) - et al.
Factors effecting impact of Aspergillus fumigatus sensitization in cystic fibrosis
Pediatr Pulmonol
(2007)
Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis
Am J Respir Crit Care Med
Correlation of IgE antibody titer to Aspergillus fumigatus with decreased lung function in cystic fibrosis
Pediatr Pulmonol
Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis
Am J Respir Crit Care Med
Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study
PLoS One
Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function?
Clin Microbiol Infect
Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients
Pediatr Pulmonol
Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis
Mycoses
Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence
Med Mycol
Lack of standardization in the procedures for mycologic examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi
Med Mycol
Standardisation of spirometry
Eur Respir J
Cited by (180)
An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples
2023, Journal of Cystic FibrosisFungal Respiratory Colonization and Infections in Cystic Fibrosis Patients in the Middle East
2024, Current Fungal Infection ReportsPulmonary Aspergillosis in People with Cystic Fibrosis
2024, Seminars in Respiratory and Critical Care MedicineABPA and AFRS: addressing prevalence, early diagnosis, allergens, and occupational concerns
2024, Journal of Asthma
This study was supported by the National Commissioning Group, National Aspergillosis Centre, University Hospital of South Manchester, United Kingdom.
Disclosure of potential conflict of interest: C. G. Baxter has received one or more payments for lecturing from or is on the speakers’ bureau for Astellas and has received one or more payments for travel/accommodations/meeting expenses from Schering Plough, Pfizer, and Merck. D. W. Denning holds founder shares in F2G Ltd, a University of Manchester spin-out company; has received grant support from F2G, the Fungal Research Trust, the Wellcome Trust, the Moulton Trust, The Medical Research Council, The Chronic Granulomatous Disease Research Trust, the National Institute of Allergy and Infectious Diseases, National Institute of Health Research, the European Union, and AstraZeneca; has acted as an advisor/consultant to F2G and Myconostica (now part of the Lab21 group) as well as other companies over the last 5 years including Pfizer, T2Biosystems, Schering Plough (now Merck), Nektar, Astellas, and Gilead; and has been paid for talks on behalf of Merck, Gilead Sciences, Astellas, Novartis, Merck, Dainippon, and Pfizer. M. D. Richardson acts as an advisor/consultant to Astellas Pharma, Merck, and Gilead Sciences and has received grant support and sponsorship from these companies; has consultancy arrangements with and has received one or more payments for the development of educational presentations for Gilead Sciences, Astellas Pharma, and Merck; has received one or more grants from or has one or more grants pending with Gilead Sciences and Astellas; has received one or more payments for lecturing from or is on the speakers’ bureau for Gilead Sciences, Astellas, and MSD; and has received royalties from Wiley-Blackwell. G. Dunn has received MRC and NIHR research grants and textbook royalties. The rest of the authors declare that they have no relevant conflicts of interest.